DE69535623D1 - Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors - Google Patents

Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors

Info

Publication number
DE69535623D1
DE69535623D1 DE69535623T DE69535623T DE69535623D1 DE 69535623 D1 DE69535623 D1 DE 69535623D1 DE 69535623 T DE69535623 T DE 69535623T DE 69535623 T DE69535623 T DE 69535623T DE 69535623 D1 DE69535623 D1 DE 69535623D1
Authority
DE
Germany
Prior art keywords
pregangans
androstanes
gaba receptor
allosteric modulation
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535623T
Other languages
English (en)
Other versions
DE69535623T2 (de
Inventor
Ravindra B Upasani
Haiji Xia
Derk Hogenkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892391&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535623(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE69535623D1 publication Critical patent/DE69535623D1/de
Application granted granted Critical
Publication of DE69535623T2 publication Critical patent/DE69535623T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69535623T 1994-02-14 1995-02-14 Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors Expired - Lifetime DE69535623T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19691994A 1994-02-14 1994-02-14
US196919 1994-02-14
US34692794A 1994-11-23 1994-11-23
US346927 1994-11-23

Publications (2)

Publication Number Publication Date
DE69535623D1 true DE69535623D1 (de) 2007-11-29
DE69535623T2 DE69535623T2 (de) 2008-07-24

Family

ID=26892391

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69535623T Expired - Lifetime DE69535623T2 (de) 1994-02-14 1995-02-14 Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors
DE69518509T Expired - Lifetime DE69518509T2 (de) 1994-02-14 1995-02-14 Androstane und pregnane zur allosterischen modulation des gaba-rezeptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69518509T Expired - Lifetime DE69518509T2 (de) 1994-02-14 1995-02-14 Androstane und pregnane zur allosterischen modulation des gaba-rezeptors

Country Status (18)

Country Link
EP (2) EP0752860B1 (de)
JP (1) JP4066272B2 (de)
KR (1) KR100338287B1 (de)
AT (2) ATE375993T1 (de)
AU (1) AU691905B2 (de)
BR (1) BR9506779A (de)
CA (1) CA2183231A1 (de)
DE (2) DE69535623T2 (de)
DK (2) DK0752860T3 (de)
ES (2) ES2296594T3 (de)
FI (2) FI118008B (de)
GR (1) GR3034810T3 (de)
HK (1) HK1014665A1 (de)
IL (1) IL112638A (de)
NO (1) NO308307B1 (de)
NZ (1) NZ282939A (de)
PT (2) PT752860E (de)
WO (1) WO1995021617A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
ATE284895T1 (de) * 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
EP1449846A1 (de) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3alpha-hydroxy-3beta Methoxymethyl-21-heterozyklish substituierte Steroide mit anesthetische Aktivität
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
ES2240222T3 (es) 1999-12-20 2005-10-16 Nicholas J. Kerkhof Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado.
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
KR20100095661A (ko) * 2005-06-09 2010-08-31 유로-셀띠끄 소시에떼 아노님 신경 자극성 스테로이드의 약학적 조성물 및 그 용도
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299010B2 (en) * 2006-09-19 2013-01-31 Solvay Pharmaceuticals Gmbh Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
ES2662500T3 (es) 2006-11-21 2018-04-06 Asarina Pharma Ab El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central
WO2008157460A1 (en) 2007-06-15 2008-12-24 Cook, Kevin, M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
LT2753632T (lt) 2011-09-08 2023-07-10 Sage Therapeutics, Inc. Neuroaktyvieji steroidai, jų kompozicijos ir naudojimas
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2766380B1 (de) * 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3-disubstituierte 19-nor-pregnan verbindungen, zusammensetzungen damit und verwendungen davon
SI2806877T1 (sl) 2012-01-23 2020-01-31 Sage Therapeutics, Inc. Nevroaktivne steroidne formulacije, ki obsegajo kompleks alopregnanolona in sulfobutil etra beta-ciklodekstrina
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN105246909B (zh) * 2013-04-17 2020-10-13 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
US9512165B2 (en) * 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
BR112016000975B1 (pt) * 2013-07-19 2020-10-06 Sage Therapeutics, Inc. Compostos esteróides neuroativos e composições compreendendo os mesmos
LT3488852T (lt) * 2013-08-23 2021-02-25 Sage Therapeutics, Inc. Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas
HRP20221294T1 (hr) * 2014-05-29 2023-03-03 Sage Therapeutics, Inc. Neuroaktivni steroidi, njihovi pripravci i uporabe
EP3157528B1 (de) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (de) 2014-09-02 2018-01-10 The Texas A&M University System Verfahren zur behandlung einer organophosphatvergiftung
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
ES2884086T3 (es) 2015-07-06 2021-12-10 Sage Therapeutics Inc Oxisteroles y sus procedimientos de uso
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
RS61718B1 (sr) 2015-07-06 2021-05-31 Sage Therapeutics Inc Oksisteroli i postupci za njihovu upotrebu
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
JOP20170059B1 (ar) 2016-03-08 2021-08-17 Sage Therapeutics Inc ستيرويدات وتركيبات نشطة عصبيًا واستخداماتها
RS63280B1 (sr) 2016-04-01 2022-06-30 Sage Therapeutics Inc Oksisteroli i postupci za njihovu upotrebu
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
DK3481845T3 (da) 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
RU2019115112A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
IL266093B2 (en) 2016-10-18 2024-02-01 Sage Therapeutics Inc Oxysterols and methods of using them
UY38213A (es) * 2018-05-04 2019-10-31 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
WO2020143640A1 (zh) * 2019-01-08 2020-07-16 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
KR20210116523A (ko) * 2019-01-14 2021-09-27 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 테트라졸론 치환된 스테로이드 및 이의 용도
KR20220016098A (ko) 2019-05-31 2022-02-08 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 조성물
CN112638928B (zh) * 2019-08-07 2023-12-22 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230416300A1 (en) * 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274179A (en) * 1964-03-19 1966-09-20 Merck & Co Inc 3-haloethynyl-3-hydroxy derivatives of the androstane-17-one and pregnane-20-one series
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0603312A4 (de) * 1991-09-13 1995-06-07 Cocensys Inc Neuer gaba a-rezeptor mit steroidbindungsstellen.
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep

Also Published As

Publication number Publication date
HK1014665A1 (en) 1999-09-30
EP1038880A3 (de) 2003-07-16
IL112638A (en) 2003-10-31
AU691905B2 (en) 1998-05-28
EP1038880B1 (de) 2007-10-17
ATE195654T1 (de) 2000-09-15
ES2296594T3 (es) 2008-05-01
DE69518509D1 (de) 2000-09-28
GR3034810T3 (en) 2001-02-28
FI118008B (fi) 2007-05-31
FI963174A (fi) 1996-09-25
JPH09510701A (ja) 1997-10-28
IL112638A0 (en) 1995-05-26
WO1995021617A1 (en) 1995-08-17
ATE375993T1 (de) 2007-11-15
PT752860E (pt) 2000-12-29
NO963355D0 (no) 1996-08-12
EP0752860A4 (de) 1998-05-06
EP0752860B1 (de) 2000-08-23
AU2090195A (en) 1995-08-29
JP4066272B2 (ja) 2008-03-26
NO963355L (no) 1996-10-11
PT1038880E (pt) 2008-01-29
DK1038880T3 (da) 2008-03-03
ES2151593T3 (es) 2001-01-01
BR9506779A (pt) 1997-10-14
FI118687B (fi) 2008-02-15
CA2183231A1 (en) 1995-08-17
DE69535623T2 (de) 2008-07-24
FI963174A0 (fi) 1996-08-13
EP0752860A1 (de) 1997-01-15
FI20051271A (fi) 2005-12-09
KR100338287B1 (ko) 2002-11-30
DK0752860T3 (da) 2000-11-13
NO308307B1 (no) 2000-08-28
DE69518509T2 (de) 2001-04-19
EP1038880A2 (de) 2000-09-27
NZ282939A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
DE69535623D1 (de) Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors
MX9703826A (es) Androstano y series del pregnano para la modulacion alosterica del receptor gaba.
ES2169727T3 (es) Compuestos heterociclicos de eter que mejoran la funcion cognitiva.
ATE407221T1 (de) Diagnostika für fragile plaque störung
MA51669B1 (fr) Modulateurs de tmem16a
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
BR9814300A (pt) Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
BR9908869A (pt) Composição para evitar ou tratar distúrbios da pele
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
DK165323C (da) Thieno-triazolo-1,4-diazepino-2-carboxylsyreamider, fremgangsmaader til fremstilling af forbindelserne, forbindelserne til anvendelse ved fremstilling af laegemidler med paf-antagonistisk virkning samt farmaceutiske praeparater indeholdende forbindelserne
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE69028513T2 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
ATE244565T1 (de) Verwendung von 2-aryl-3-aroylbenzo(b)thiophene zur behandlung des oestrogenenthaltungssyndroms
PT852153E (pt) Dispositivo para substituir sondas respiratorias na traqueia de um paciente
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE463745T1 (de) Differentielle diagnose von neurologischen krankheiten
ATE112256T1 (de) 9-amino-2-phenylbicyclo(3.3.1>nonane und 9-amino- 2-phenylbicyclo(3.3.1>-non-2-ene und diese enthaltende therapeutische mittel.
UA33113A (uk) Спосіб визначення cтруктури нафтонасичення порід-колекторів
GORDIS The Exegesis of Mishna and Baraita of Rav and Samuel. Part One: Sources of Laws and’Uqimtas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition